Facioscapulohumeral dystrophy

Seminars in Neurology

Volumn 19, Issue 1, 1999, Pages 35-43

  Kissel, John T ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Chromosome 4q35; Facioscapulohumeral; Muscular dystrophy; Position effect variegation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CREATINE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALBUTAMOL;

AUTOSOMAL DOMINANT DISORDER; BRACE; CHROMOSOME 4Q; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENETIC LINKAGE; HUMAN; MOLECULAR GENETICS; MUSCLE EXERCISE; MUSCLE STRETCHING; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; ORTHOSIS; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0032984212     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040824     Document Type: Review

References (64)

1. Tawil R, Figlewicz DA, Griggs RC, Weiffenbach B. Facioscapulohumeral dystrophy. A distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Ann Neurol 1998;43:279-282
2. Padberg G. Facioscapulohumeral disease. Thesis. Leiden, The Netherlands: University of Leiden, 1982
3. Wijmenga C, Frants RR, Brouwer OF. et al. Location of the facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990;336:651-653
4. Duchenne GB. Recherches sur la paralysis musculaire pseudohypertophique, ou paralysis myosclerosique. Arch Gen Med 1868;11:5-25,179-209,305-321,421-443,552-588
5. Landouzy L, Dejerine J. De la myopathie atrophique progressive (myopathie héréditaire debutant dans l'enfance, par la face sans alteration du système nerveux). CR Seances Acad Sci 1884;98:53
6. Munsat TL. Facioscapulohumeral disease and the scapuloperoneal syndrome. In: Franzini-Armstrong C, Engel AG, eds. Myology; 2nd edition. New York: McGraw-Hill, 1994:1220-1232
7. Tyler FH, Stephens FE. Studies in disorders of muscles. II. Clinical manifestations and inheritance of facioscapulohumeral dystrophy. Ann Intern Med 1950;32:640-660
8. Walton JN, Nattrass FJ. On the classification, natural history and treatment of the myopathies. Brain 1954;77:169-231
9. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nature Genet 1992;2:26-30
10. Tawil R, Griggs RC. Facioscapulohumeral muscular dystrophy. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, eds. The molecular and genetic basis of neurological disease. Boston: Butterworth-Heinemann. 1997:931-938
11. Brouwer OF, Padberg GW, et al. Early onset facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;2:S67-S72
12. Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 1994;51:387-394
13. Okinaga A, Matsuoka T, Umeda J, et al. Early-onset facioscapulohumeral muscular dystrophy: Two case reports. Brain Dev 1997;19:563-567
14. Hansen PA, Rowland LP. Mobius syndrome and facioscapulohumeral muscular dystrophy. Arch Neurol 1971;24:31-39
15. Lunt PW, Compston DA, Harper PS. Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimizing ascertainment bias. J Med Genet 1989;26:755-760
16. Awerbuch GI, Nigro MA. Beevor's sign in facioscapulohumeral muscular dystrophy. Arch Neurol 1990;47:1208-1209
17. Anonymous. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): Implications for therapeutic trials. The FSH-DY Group. Neurology 1997;48:38-46
18. Tawil R, McDermott MP, Mendell JR, et al., and the FSH-DY Group. Facioscapulohumeral muscular dystrophy (FSHD): Design of natural history study and results of baseline testing. Neurology 1994;44:442-446
19. Brouwer OF, Padberg GW, Van der Ploeg RJO, et al. The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy. Brain 1992; 115:1587-1598
20. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995;4:951-958
21. Fitzsimons RB, Gurwir EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. Brain 1987; 110:631-684
22. Desai UR, Sabates FN. Long-term follow-up of facioscapulohumeral muscular dystrophy and Coats' disease. Am J Ophthalmol 1990;110:568-559
23. Brouwer OF, Padberg GW, Ruys CJM, et al. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology 1991;31: 1878-1881
24. Padberg GW, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;2:S73-S80
25. Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: Evidence for selective genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292-299
26. De Visser M, DeVoogt GW, La Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral muscular dystrophy and Bethlem myopathy. Muscle Nerve 1992;15:591-596
27. Caponnetto S, Pastorini C, Tirelli G. Persistent atrial standstill in a patient affected with facioscapulohumeral dystrophy. Cardiologia 1968;53:341-350
28. Bloomfield DA, Sinclair-Smith BC. Persistent atrial standstill. Am J Med 1965;39:335-340
29. Furukawa T. Neurogenic FSH muscular atrophy. Muscle Nerve 1995;2:S96-S97
30. Bodensteiner JB, Shochet SS. Facioscapulohumeral muscular dystrophy: The choice of a biopsy site. Muscle Nerve 1986;9: 544-547
31. Arahata K, Ishihara T, Fukunaga H, et al. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): Immunocytochemical and genetic analyses. Muscle Nerve 1995;2: S56-S66
32. Munsat TL, Piper D, Cancilla P, Mednick J. Inflammatory myopathy with facioscapulohumeral distribution. Neurology 1972;22: 335-347
33. Molnar M, Dioszeghy P, Mechler F. Inflammatory changes in facioscapulohumeral muscular dystrophy. Eur Arch Psychiatry Clin Neurosci 1991;241:105-108
34. Altherr MR, Bengtsson U, Markovich RP, Winokur ST. Efforts toward understanding the molecular basis of facioscapulohumeral muscular dystrophy. Muscle Nerve 1995;2:S32-S38
35. Fisher J, Upadhyaya M. Molecular genetics of facioscapulohumeral muscular dystrophy (FSHD). Neuromusc Disord 1997; 7:55-62
36. Padberg GW, Frants RR, Brouwer OF, et al. Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve 1995;2(Suppl):S81-S84
37. Kohler J, Rupilius B, Otto M, Bathke K, Koch MC. Germline mosaicism in 4q35 facioscapulohumeral muscular dystrophy (FSHD1A) occurring predominantly in oogenesis. Hum Genet 1996;98:485-490
38. Deidda G, Cacurri S, Piazzo N, Felicetti L. Direct detection of 4q35 rearrangements implicated in facioscapulohumeral muscular dystrophy (FSHD). J Med Genet 1996;33:361-365
39. Zatz M, Marie SK, Cerqueira A, et al. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet 1998; 77:155-161
40. Deidda G, Cacurri S, Grisanti P, et al. Physical mapping evidence for a duplicated region on chromosome 10qter showing high homology with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter. Eur J Hum Genet 1995;3:155-167
41. van Deutekom JC, Bakker E, Lemmers RJ, et al. Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: Implications for genetic counseling and etiology of FSHD1. Hum Mol Genet 1996;5:1997-2003
42. Lemmers Rjlf, van der Maarel SM, van Deutekom JCT, et al. Inter-and intrachromosomal sub-telomeric rearrangements on 4q35: Implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Hum Mol Genet 1998; 7:1207-1214
43. Van Deutekom JCT, Wijmenga C, Van Tienhoven EAE, et al. FSHD associated DNA rearrangements are due to large deletions of integral copies of a 3.2 Kb tandemly repeated unit. Hum Mol Genet 1993;2:2037-2042
44. Hsu YD, Kao MC, Shyu WC, et al. Application of chromosome 4q35-qter marker (pFR-1) for DNA rearrangement of facioscapulohumeral muscular dystrophy patients in Taiwan. J Neurol Sci 1997;149:73-79
45. Griggs RC, Tawil R, Storvick D, et al. Genetics of facioscapulohumeral muscular dystrophy: New mutations in sporadic cases. Neurology 1993;43:2369-2372
46. Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 1995;56:99-105
47. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. Ann Neurol 1996;39:744-748
48. Griggs RC, Tawil R, McDermott M, et al. Monozygotic twins with facioscapulohumeral dystrophy (FSHD): Implications for genotype/phenotype correlations. Muscle Nerve 1995;2:S50-S55
49. Winokur ST, Bengtsson U, Feddersen J. et al. The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: Implications for a role of chromatin structure in the pathogenesis of the disease. Chromosom Res 1994;2:225-234
50. Weiffenbach B, Dubois J, Storvick D, et al. Mapping the facioscapulohumeral muscular dystrophy gene is complicated by chromosome 4q35 recombination events. Nature Genet 1993; 4:165-169
51. van Deutekom JC, Lemmers RJ, Grewal PK, et al. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum Mol Genet 1996;5:581-590
52. Gilbert JR, Stajich JM, Wall S, et al. Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD). Am J Hum Genet 1993;53:401-408
53. Lunt PW. Report of the sixth International Workshop on Facioscapulohumeral Muscular Dystrophy. San Francisco, 11 November 1992; and current guidelines for clinical application of DNA rearrangements at locus D4S810. Neuromusc Disord 1994;4:83-86
54. Padberg GW, Lunt PW, Koch M, Fardeau M. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromusc Disord 1991;4:231-234
55. Milanov I, Ishpekova B. Differential diagnosis of scapuloperoneal syndrome. Electromyogr Clin Neurophysiol 1997;37:73-78
56. Tawil R, Myers GJ, Weiffenbach B, Griggs RC. Scapuloperoneal syndromes. Absence of linkage to the 4q35 FSHD locus. Arch Neurol 1995;52:1069-1072
57. Wilhelmsen KC, Blake DM, Lynch T, et al. Chromosome 12-linked autosomal dominant scapuloperoneal muscular dystrophy. Ann Neurol 1996;39:507-520
58. Munsat TL, Serratrice G. Facioscapulohumeral and scapuloperoneal syndromes. In: Vinken PJ, Bruyn GW, Klawans H, eds. Handbook of clinical neurology. Vol 62, rev 18. Myopathies. Amsterdam: Elsevier Science, 1992:162-177
59. Verma A, Bradley WG. Autosomal dominant limb-girdle muscular dystrophy. In: Lane RJM, ed. Handbook of muscle disease. New York: Marcel Dekker, 1996:287-309
60. Bunch WH, Siegel IM. Scapulothoracic arthrodesis in facioscapulohumeral muscular dystrophy. Review of seventeen procedures with three to twenty-one-year follow-up. J Bone Joint Surg (AM) 1993;75:372-376
61. Heller KD, Prescher A, Forst J, Stadtmuller A, Forst R. Anatomo-experimental study for lace fixation of winged scapula in muscular dystrophy. Surg Radiol Anat 1996;18:75-79
62. Jakab E, Gledhill RB. Simplified technique for scapulocostal fusion in facioscapulohumeral dystrophy. J Pediatr Orthop 1993; 13:749-751
63. Tawil R, McDermott MP, Pandya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. Neurology 1997;48:46-49
64. Kissel JT, McDermott MP, Natarajan R, et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1998;;50:1402-1406